Medicare Part D drugs starting with Z
64 drugs start with Z; 18 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Zenpep in 2024: $597 million, what plans and patients paid at the pharmacy before rebates.
Which drugs start with Z?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Zafemy (ethinyl estradiol / norelgestromin) | 92.7% | Tier 3 | $659 thousand |
| Zafirlukast | 96.6% | Tier 4 | $7 million |
| Zaleplon | 75.6% | Tier 1 | $4 million |
| Zarontin (ethosuximide) | 0.2% | Tier 1 | $67 thousand |
| Zarxio (filgrastim-sndz) | 76.4% | Tier 5 | $48 million |
| Zavzpret (zavegepant) | 5.2% | Tier 3 | $9 million |
| Zegalogue (dasiglucagon) | 44.6% | Tier 3 | $192 thousand |
| Zejula (niraparib) | 100% | Tier 5 | $224 million |
| Zelapar (selegiline hydrochloride) | 2.7% | Tier 5 | $1 million |
| Zelboraf (vemurafenib) | 100% | Tier 5 | $13 million |
| Zelsuvmi (berdazimer) | 4.5% | Tier 5 | no 2024 match |
| Zelvysia (sapropterin dihydrochloride) | 51.9% | Tier 5 | no 2024 match |
| Zemaira (alpha 1-proteinase inhibitor, human) | 31.7% | Tier 5 | $33 million |
| Zemdri (plazomicin) | 0.5% | Tier 5 | no 2024 match |
| Zenatane (isotretinoin) | 94.5% | Tier 4 | $543 thousand |
| Zenpep (amylase / lipase / protease) | 94% | Tier 3 | $597 million |
| Zenzedi (dextroamphetamine sulfate) | 21.9% | Tier 4 | $281 thousand |
| Zepbound (tirzepatide) | 0.5% | Tier 5 | $387 thousand |
| Zeposia (ozanimod) | 4.2% | Tier 5 | $91 million |
| Zerbaxa (ceftolozane / tazobactam) | 4% | Tier 5 | $18 million |
| Zerviate (cetirizine) | 25% | Tier 4 | $4 million |
| Zestoretic (hydrochlorothiazide / lisinopril) | under 0.1% | Tier 1 | $696 thousand |
| Zestril (lisinopril) | under 0.1% | Tier 1 | $3 million |
| Zetia (ezetimibe) | under 0.1% | Tier 1 | $6 million |
| Zevtera (ceftobiprole medocaril sodium) | 0.3% | Tier 5 | no 2024 match |
| Ziagen (abacavir) | under 0.1% | Tier 1 | $12 thousand |
| Zidovudine | 100% | Tier 2 | $169 thousand |
| Ziextenzo (pegfilgrastim-bmez) | 4.5% | Tier 5 | $3 million |
| Zilbrysq (zilucoplan) | 2.3% | Tier 5 | $37 million |
| Zileuton | 2.9% | Tier 5 | $26 million |
| Zioptan (tafluprost) | 0.3% | Tier 4 | $8 million |
| Ziprasidone | 100% | Tier 2 | $41 million |
| Zirgan (ganciclovir) | 90.1% | Tier 4 | $9 million |
| Zithromax (azithromycin) | 0.3% | Tier 4 | $20 thousand |
| Zituvimet (metformin hydrochloride / sitagliptin) | 0.1% | Tier 3 | no 2024 match |
| Zocor (simvastatin) | under 0.1% | Tier 1 | $2 million |
| Zokinvy (lonafarnib) | 25.1% | Tier 5 | no 2024 match |
| Zolinza (vorinostat) | 100% | Tier 5 | $4 million |
| Zolmitriptan | 18.3% | Tier 2 | $8 million |
| Zoloft (sertraline) | under 0.1% | Tier 1 | $14 million |
Show the other 24 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Zolpidem tartrate | 100% | Tier 2 | $61 million |
| Zomacton (somatropin) | 0.1% | Tier 4 | $62 thousand |
| Zomig (zolmitriptan) | 0.4% | Tier 2 | $255 thousand |
| Zonalon (doxepin hydrochloride) | under 0.1% | Tier 1 | $12 thousand |
| Zonegran (zonisamide) | under 0.1% | Tier 1 | $21 million |
| Zonisade (zonisamide) | 100% | Tier 4 | $4 million |
| Zonisamide | 100% | Tier 2 | $14 million |
| Zortress (everolimus) | 0.1% | Tier 1 | $1 million |
| Zoryve (roflumilast) | 38.5% | Tier 4 | $26 million |
| Zosyn (piperacillin / tazobactam) | 8.1% | Tier 4 | $673 thousand |
| Zovia 1/35E (ethinyl estradiol / ethynodiol diacetate) | 95.2% | Tier 2 | no 2024 match |
| Zovirax (acyclovir) | under 0.1% | Tier 1 | $170 thousand |
| Ztalmy (ganaxolone) | 100% | Tier 5 | $2 million |
| ZTlido (lidocaine) | 9.6% | Tier 3 | $50 million |
| Zubsolv (buprenorphine / naloxone) | 21.8% | Tier 3 | $26 million |
| Zurnai (nalmefene) | 19.3% | Tier 3 | no 2024 match |
| Zurzuvae (zuranolone) | 100% | Tier 5 | $544 thousand |
| Zydelig (idelalisib) | 100% | Tier 5 | $4 million |
| Zykadia (ceritinib) | 100% | Tier 5 | $5 million |
| Zylet (loteprednol etabonate / tobramycin) | 31.8% | Tier 3 | $3 million |
| Zymfentra (infliximab-dyyb) | 4.1% | Tier 5 | $2 million |
| Zypitamag (pitavastatin magnesium) | 19.6% | Tier 4 | $4 million |
| Zyprexa (olanzapine) | 16.9% | Tier 4 | $12 million |
| Zyvox (linezolid) | 0.2% | Tier 1 | $74 thousand |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans